J. Goldman & CO LP Avadel Pharmaceuticals PLC Call Options Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding AVDL
# of Institutions
8Shares Held
1.07MCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$6.44 Million3.88% of portfolio
-
Knott David M Jr Syosset, NY332KShares$3.56 Million1.53% of portfolio
-
Schulhoff & CO Inc137KShares$1.47 Million0.81% of portfolio
-
1620 Investment Advisors, Inc. Plymouth, MA1KShares$10,7300.01% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$5,3650.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $650M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...